One patient was treated with the antidote twice with an interval of 2 months between treatments. The decision to reverse dabigatran with idarucizumab was made by the treating clinicians, as was the assessment of clinical outcomes and blood sampling/monitoring (activated partial thromboplastin time, thrombin time and diluted thrombin time) before and after use. We analysed consecutive cases treated with idarucizumab in Slovenia from January to October 2016. To evaluate efficacy and safety of the clinical use of idarucizumab after its availability in Slovenia. Real-life experience with idarucizumab, which reverses the anticoagulant effect of dabigatran, is currently limited.
0 kommentar(er)
